# XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

Source: https://onco.cc/trials/nct07688577/  
OnCo record `nct07688577` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in lung cancer, run by Xilio Development, Inc., not yet recruiting.

## Summary

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07688577 by Xilio Development, Inc., with a registry enrolment figure of 140 participants, started 2026-08 and due to reach its primary completion in 2029-11. Interventions recorded: XTX501. Conditions listed: Metastatic NSCLC - Non-Small Cell Lung Cancer; Advanced Solid Tumor. Primary outcome: Incidence of Dose Limiting Toxicities (DLTs) in Part 1A; Incidence of treatment-emergent adverse events (Phase 1 and Phase 2); Incidence of serious adverse events (Phase 1 and Phase 2). Lung eligibility wording from the registry: "* Metastatic NSCLC:". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07688577
- Phase: 1/2
- Setting: A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX501 in Participants With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
- Sponsor: Xilio Development, Inc.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT07688577: https://clinicaltrials.gov/study/NCT07688577

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Xilio Therapeutics](https://onco.cc/companies/xilio-therapeutics/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07688577.json